All AbMole products are for research use only, cannot be used for human consumption.
β-catenin-IN-2 is a potent β-catenin inhibitor, compound H1B1, extracted from patent US20150374662A1. β-catenin-IN-2 can be used for the study of colorectal cancer.
| Molecular Weight | 255.29 |
| CAS Number | 1458664-10-2 |
| Solubility (25°C) | DMSO 83.33 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Wnt/beta-catenin Products |
|---|
| (9Z,12Z,15Z)-N-[(3-Methoxyphenyl)methyl]-9,12,15-octadecatrienamide
(9Z,12Z,15Z)-N-[(3-Methoxyphenyl)methyl]-9,12,15-octadecatrienamide is a macamide isolated from Maca (Lepidium meyenii Walp). (9Z,12Z,15Z)-N-[(3-Methoxyphenyl)methyl]-9,12,15-octadecatrienamide induces mesenchymal stem cells osteogenic differentiation and consequent bone formation through activating the canonical Wnt/β‐catenin signaling pathway. |
| F7H
F7H is a Frizzled receptor FZD7 antagonist with IC50 of 1.25 μM. F7H is a potent ligand for the FZD7 transmembrane domain (TMD). |
| UU-T02
UU-T02 is a novel potent, selective small-molecule inhibitor of β-Catenin/T-cell factor protein-protein interaction, with a Ki of 1.36 μM. UU-T02 inhibits canonical Wnt signaling. |
| Wnt/β-catenin agonist 1
Wnt/β-catenin agonist 1 is a Wnt/β-catenin signalling pathway agonist, with an EC50 of 0.27 μM. |
| Calphostin C
Calphostin C (PKF115-584) is a small molecule inhibitor of Wnt/beta-catenin/lef-1 signaling. Calphostin C is also a potent and specific inhibitor of protein kinase C. PKF115-584 efficiently killed CLL cells (LC(50)<1 microM), whereas normal B cells were not significantly affected. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
